Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

Clavien‐Dindo grade ≤ 2 complications8 · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…

It is very uncertain whether impact of extended changes clavien‐Dindo grade ≤ 2 complications8 compared with standard lymph node dissection on overall survival among patients… (very low certainty).

1 finding from 1 review

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

Disease‐specific quality of life · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Tardive dyskinesia: Not improved to a clinically important extent · patients with antipsychotic‐induced TD

The intervention may leads to lower tardive dyskinesia: Not improved to a clinically important extent (low certainty).

1 finding from 1 review

Intervention not reported

Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced TD

It is very uncertain whether the intervention changes tardive dyskinesia: Deterioration of symptoms (very low certainty).

1 finding from 1 review

Intervention not reported

Acceptability of treatment: Leaving the study early · patients with antipsychotic‐induced TD

It is very uncertain whether the intervention changes acceptability of treatment: Leaving the study early (very low certainty).

1 finding from 1 review

Intervention not reported

Social confidence, social inclusion, social networks, or personalised quality of life measures · patients with antipsychotic‐induced TD

The review found no eligible studies for this question.

1 finding from 1 review

Single dose primaquine at 0.2 to 0.25 mg/kg vs no primaquine, with artemisinin partner,

Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment

Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).

2 findings from 1 review

Single dose primaquine at 0.4 to 0.5 mg/kg vs no primaquine, with artemisinin partner,

Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment

Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (low certainty).

1 finding from 1 review

Single dose primaquine at 0.75 mg/kg vs no primaquine, with artemisinin partner,

Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment

Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).

2 findings from 1 review

Single dose primaquine at 0.75 mg/kg vs no primaquine, with artemisinin partner,

Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment

Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).

1 finding from 1 review

Single dose primaquine at 0.75 mg/kg vs no primaquine, with artemisinin partner,

Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment

Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).

1 finding from 1 review

Single dose primaquine at 0.4 to 0.5 mg/kg vs no primaquine, with non‐artemisinin partner,

Participants with gametocytes at day 4‐5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment

Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).

1 finding from 1 review

Single dose primaquine at 0.4 to 0.5 mg/kg vs no primaquine, with non‐artemisinin partner,

Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment

Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).

1 finding from 1 review

Single dose primaquine at 0.75 mg/kg vs no primaquine, with non‐artemisinin partner,

Participants infectious at day 8 · adults and children with malaria being treated with non‐artemisinin treatment

It is very uncertain whether single dose primaquine at 0.75 mg/kg changes participants infectious at day 5 compared with no primaquine, with non‐artemisinin partner, (very low certainty).

2 findings from 1 review

Single dose primaquine at 0.75 mg/kg vs no primaquine, with non‐artemisinin partner,

Participants with gametocytes at day 5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment

Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 5, by microscopy compared with no primaquine, with non‐artemisinin partner, (low certainty).

1 finding from 1 review

Single dose primaquine at 0.75 mg/kg vs no primaquine, with non‐artemisinin partner,

Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment

Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).

1 finding from 1 review

Single dose primaquine at 0.2 to 0.25 mg/kg vs no primaquine, with artemisinin partner,

Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment

Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).

1 finding from 1 review